Polycystic Ovarian Syndrome
01 Jan 2017-
About: The article was published on 2017-01-01 and is currently open access. It has received None citations till now. The article focuses on the topics: Hyperandrogenism.
References
More filters
TL;DR: Evaluating prescribing preferences for COCs, concomitant use of spironolactone, and utilization of metformin in women with PCOS suggests further attention is needed to medication management of PCOS to bridge the gap between guidelines and practice.
Abstract: The October 2010 ESHRE/ASRM polycystic ovary syndrome (PCOS) workshop concluded: (1) all combined oral contraceptives (COC) appear to have equal efficacy for PCOS, (2) addition of antiandrogens (spironolactone) to COCs has little treatment benefit and (3) metformin does not improve the live-birth rate and should only be used with impaired glucose tolerance. We compared these guidelines to current practice in the United States IMS claims-database. Time-series analyses were conducted by calendar-year in women with PCOS to evaluate prescribing preferences for COCs, concomitant use of spironolactone, and utilization of metformin. Trends were analyzed with linear regression. Our cohort included 1.6 million women taking COCs, 46 780 with a PCOS claim. Drospirenone utilization increased by 1.52% (SE:0.48%, p = 0.007) per-year more in women with PCOS (4.16%, SE:0.45%, p < 0.001) than in women without PCOS (2.64%, SE:0.17%, p < 0.001)). Concomitant use of drospirenone and spironolactone was common (14.26%) and increased by 0.75% (SE:0.15%, p = 0.002) per-year. Although plasma glucose tests were unavailable, women with PCOS were more likely to take metformin than have a diabetes claim (45.8% versus 15.2%, p < 0.001), indicating some women likely receive metformin solely for PCOS. Our data suggests further attention is needed to medication management of PCOS to bridge the gap between guidelines and practice.
19 citations
Journal Article•
TL;DR: PCOS is likely underdiagnosed, especially in adolescent patients, and challenging to make a diagnosis during the 1–2 years following menarche because normal pubertal changes can mimic features of PCOS.
Abstract: PCOS is likely underdiagnosed, especially in adolescent patients. It is challenging to make a diagnosis during the 1–2 years following menarche because normal pubertal changes can mimic features of PCOS.
5 citations